Cancer-related fatigue and chemotherapy-associated adverse effects: correlation with TNF-α, IL-1 and 17-hydroxycorticosteroids. (July 2014)

• Record Type: Journal Article
• Authors: Zhang, Shuyao; Zeng, De; Peng, Yuhui; Yang, Yuxian; Zhuang, Xiaowen; Li, Zongtai; Wang, Miaojun; Chen, Lei; Zhang, Hao
• Is Part Of: Future oncology. Volume 10:Number 9(2014)
• Page Start: 1619
• Page End: 1626
• Publication Date: 2014-07
• Subjects: 17-HCS -- 17-hydroxycorticosteroids -- cancer-related fatigue -- IL-1 -- TNF-α; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.14.15
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT: Aim: We sought to determine the relationship between cancer-related fatigue, chemotherapy-associated adverse effects in patients with advanced stages of cancer, and the levels of TNF-α, IL-1 and 17-hydroxycorticosteroids (17-HCS).Patients & methods: Two hundred cancer patients were recruited. They were given a Cancer Fatigue Scale survey to assess their general state of health before and after chemotherapy. Their plasma levels of TNF-α and IL-1 and urine levels of 17-HCS were also measured.Results: Increased levels of TNF-α and IL-1 are common in cancer patients. Thirty-five (17.5%) patients suffered from chemotherapy-associated adverse effects, but their plasma levels of TNF-α and IL-1 were not significantly elevated after chemotherapy. However, the urinary levels of 17-HCS levels were significantly elevated in 23 patients after chemotherapy.Conclusion: Patients who had elevated urinary levels of 17-HCS before chemotherapy are accompanied by chemotherapy-associated adverse effects. Thus, elevated 17-HCS in urine could be a possible predictor for chemotherapy-associated adverse effects.